Harrow, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US4158581094
USD
46.77
6.6 (16.43%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Harrow, Inc. stock-summary
stock-summary
Harrow, Inc.
Pharmaceuticals & Biotechnology
Harrow Health, Inc., formerly Imprimis Pharmaceuticals, Inc., owns diversified portfolio of healthcare businesses. The Company’s subsidiaries are Imprimis Pharmaceuticals Inc. and Park Compounding. Imprimis Pharmaceuticals Inc. is engaged in ophthalmology pharmaceutical compounding business. Park Compounding is engaged in compounding business and also offers strategic research and development facilities, which is engaged in developing and dispensing medicines for individual patients.
Company Coordinates stock-summary
Company Details
102 WOODMONT BLVD, SUITE 610 , NASHVILLE TN : 37215
stock-summary
Tel: 1 615 7334731
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 46 Schemes (18.26%)

Foreign Institutions

Held by 70 Foreign Institutions (6.05%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Dr. Robert Kammer
Independent Chairman of the Board
Mr. Mark Baum
Chief Executive Officer, Director
Dr. Richard Lindstrom
Director
Ms. Teresa Sparks
Independent Director
Prof. R. Lawrence Van Horn
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
64 Million
(Quarterly Results - Jun 2025)
Net Profit:
5 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,472 Million (Small Cap)

stock-summary
P/E

NA (Loss Making)

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

3.42

stock-summary
Return on Equity

-20.09%

stock-summary
Price to Book

29.64